Novo may gain more than expected from Medicare obesity drug pilot
STAT reports the Trump administration's Bridge program already covers obesity drugs for seniors at $245 a month, terms favorable to both incretin makers.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 22 10:23 ETSource: STAT
The wire
- 01STAT reports that Novo Nordisk may be getting better terms than anticipated under Medicare's Bridge pilot, which covers obesity medicines for seniors at $245 a month.
- 02The pilot sets a reference point for what Medicare and cash-pay patients will pay for semaglutide and tirzepatide, shaping telehealth and compounding pricing pressure.
- 03Details of the arrangement remain behind STAT's paywall, and the program's effect on uptake, coverage rules and net pricing has yet to be seen.
From the source
Read at statnews.comSTAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
Eli Lilly and Novo Nordisk were already benefitting a great deal from the Trump administration's pilot program covering obesity drugs for seniors at a price of $245 a month. It…